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Systematic reviewa b s t r a c t
Background: A lower conversion vaccination rate and a more rapid decline in antibody titers over time in
dialysis patients raise concerns about the effectiveness of pneumococcal vaccination (PV) in this popula-
tion, which has not been systematically reviewed.
Methods: We searched PubMed, Cochrane Library, Embase and three Chinese databases from inception
until February 29th, 2020 for interventional, cohort and case–control studies evaluating PV alone or com-
bined with influenza vaccination (IV) on outcomes (all-cause mortality, pneumonia, cardiovascular
events, antibody response and safety). Independent reviewers completed citation screening, data extrac-
tion, risk assessment, meta-analysis, and GRADE rating of the quality of evidence.
Results: Five cohort studies and one quasirandomized control trial enrolling 394,299 dialysis patients
with high to moderate quality were included. Compared with unvaccinated individuals, those receiving
PV had lower risk of all-cause mortality [Adjusted relative risk (RR) 0.73, 95% CI 0.67–0.79, I2 = 31.1%,
GRADE low certainty] and cardiovascular events (adjusted RR 0.80, 95% CI 0.69–0.93, I2 = 47.2%,
GRADE low certainty) without serious adverse effect reported. Compared with no vaccination, lower
all-cause mortality was observed in those receiving PV combined with IV (Adjusted RR 0.71, 95%CI
0.67–0.75, I2 = 63.3%), PV alone (Adjusted RR 0.86, 95% CI 0.78–0.94,I2 = 0%], and IV alone (Adjusted RR
0.76, 95% CI 0.73–0.79, I2 = 0%]. There was no difference between pneumococcal vaccinated patients vs
non-vaccinated patients with respect to pneumonia. Immune response to pneumococcal conjugate
vaccine-13 was weaker in polysaccharide pneumococcal vaccine-23-pre-vaccinated compared with
vaccine-naive patients.
Conclusions: The use of pneumococcal vaccine especially combined with influenza vaccination is associ-
ated with lower risks of all-cause mortality but may be affected by residual confounding/healthy vaccinee
bias.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under theCCBY license (http://
creativecommons.org/licenses/by/4.0/).hou city,
Y. Mo, J. Zeng, C. Xiao et al. Vaccine 38 (2020) 7422–7432Contents1. Background. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7423
2. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74232.1. PRISMA-guideline and study protocol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7423
2.2. Eligibility criteria. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7423
2.3. Outcome measurement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7423
2.4. Literature search . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7424
2.5. Data selection and extraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7424
2.6. Risk of bias assessment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7424
2.7. Assessment of the quality of a body of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7424
2.8. Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74243. Results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7424
3.1. Selection of studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7424
3.2. Study characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7424
3.3. Risk of bias assessment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7424
3.4. All-cause mortality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7425
3.5. Cardiovascular events . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7425
3.6. Incident pneumonia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7428
3.7. Antibody response. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7428
3.8. Safety . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7428
3.9. Publication bias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74284. Discussion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7428
4.1. Policy implication . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7430
4.2. Strengths and limitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74305. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7431
CRediT authorship contribution statement. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7431
Declaration of Competing Interest. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7431
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7431
Funding/Support . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7431
Role of Funder/Sponsor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7431
Appendix A. Supplementary material . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7431
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74311. Background
End-stage kidney disease (ESKD) is a globally prevalent chronic
condition. According to a recent global survey, the median preva-
lence of kidney replacement therapy globally was around 759
per million population [1]. As a significant major complication of
ESKD, infection is second to cardiovascular disease as the leading
cause of death in people with ESKD, contributing to excess morbid-
ity and health care costs [2]. Among those who die from infection,
pneumonia is one of the most common reasons [3]. In dialysis
patients, the risk of death from pneumonia was 14- to 16-fold
higher than that in the general population [4] while streptococcus
pneumoniae was the most common causative pathogen of pneu-
monia [5].
To reduce pneumococcal pneumonia burden on dialysis
patients, global and national guidelines have been established
to recommend that dialysis patients receive vaccination with
pneumococcal vaccine(PV) per five years and influenza vaccine
(IV) yearly [6,7]. However, some studies have indicated that
patients receiving dialysis have a lower conversion vaccination
rate and a more rapid decline in antibody titers over time [8,9].
These observations have raised some concerns and questions in
relation to PV in dialysis patients: (1) whether PV works or
not; (2) whether PV combined with IV is more effective than
either agent alone; (3) the duration of protective effect; and,
(4) whether pneumococcal conjugate vaccine 13 (PCV-13) or
polysaccharide pneumococcal vaccine 23 (PPV-23) is more
effective?
Here, we performed a systematic review and meta-analysis that
summarized the available evidence on the effectiveness and safety
of PV in the dialysis population.74232. Methods
2.1. PRISMA-guideline and study protocol
The systematic review and meta-analysis was conducted in
compliance with the ‘‘Preferred Reporting Items for Systematic
Reviews and Meta-analyses” guidelines [10] and was prospectively
registered with the international prospective register of systematic
reviews (PROSPEOR Registration ID: CRD42019137874 and see
Supplementary Item 1).
2.2. Eligibility criteria
We included randomized control trials or observational studies
(cohort or case control studies) that assessed the effectiveness and/
or safety of PV (alone or combined with IV) in ESKD patients
receiving peritoneal dialysis (PD) or hemodialysis (HD), regardless
of publication status and language. The intervention group
included PV regardless of adjuvant IV, route of administration or
dose. The control group was either unvaccinated or received
placebo.
2.3. Outcome measurement
Primary outcomes were all-cause mortality, incident pneumo-
nia and cardiovascular events. Secondary outcomes were antibody
response and safety. All-cause mortality was identified from med-
ical record. Incident pneumonia was hospitalizations from pneu-
monia regardless of pathogen. Cardiovascular events included
death or hospitalizations from myocardial infarction, heart failure
and unstable angina. Antibody titer could be measured by different
Y. Mo, J. Zeng, C. Xiao et al. Vaccine 38 (2020) 7422–7432assays at different periods. As for safety, we considered all types of
local and systemic adverse events reported in the included studies.2.4. Literature search
We searched PubMed, Cochrane Library, Embase, three Chinese
databases (China National Knowledge Infrastructure, China Biology
Medicine and Wangfang databases) and reference list from incep-
tion until February 29th, 2020 for studies on PV (combined with or
without IV) in dialysis patients.
Our search strategy included the relevant key terms: ‘‘dialysis”
and ‘‘pneumococcal vaccine”. We used the key words/MeSH terms
in the key papers obtained from PubMed reminder to adapt the
searching strategies (For the full strategies in Pubmed see Supple-
mentary Item 2).2.5. Data selection and extraction
All the search records from different databases were imported
in ENDNOTE. After deduplication, eligible studies were listed and
assessed independently by three authors (Y.M., J. Z, & C.X.). We
independently screened titles, abstracts and full text articles, and
the reasons for exclusion have been given. Disagreements between
the review authors over article screening were resolved by discus-
sion, with the involvement of a fourth review author (G.S.).
Two authors (Y.M. & J. Z.) used pre-defined forms to extract data
from the studies. The following information was extracted: author,
country, year, study design, study population, age of participants,
years on dialysis, vaccine profile, study size, relative risks (RRs),
and 95% confidence intervals (95% CIs), confounders, confounder-
adjusted effect measure and side effects. If the RR was not available
in the studies, the numbers or incidences of the outcomes were
extracted to calculate the RRs.2.6. Risk of bias assessment
Two authors (Y.M. & L.Z.) independently assessed the risk of
bias. The Cochrane Collaboration’s tool for assessing risk of bias
was used for randomized controlled trials (RCTs): sequence gener-
ation; allocation concealment; blinding of participants, staff and
outcome assessors; completeness of outcome data and evidence
of selective outcome reporting and other potential threats to valid-
ity [11]. The Newcastle-Ottawa Scale (NOS) tool was used for
cohort studies: selection of study participants (scores 0–4), compa-
rability of subjects (scores 0–2), and exposure or outcome (scores
0-3), with the total score ranging from 0 to 9 (quality of study:
low < 4; moderate: 4–<7; high  7– <8) [12]. Disagreements
between the review authors over the risk of bias were resolved
by discussion, with involvement of a third review author (G.S.).2.7. Assessment of the quality of a body of evidence
For each outcome, the quality of the respective body of evidence
was assessed using the GRADE methodology [13]. According to
GRADE, evidence on the effects of an intervention was categorized
into four levels of certainty: very low, low, moderate, and high.
Bodies of evidence from RCTs start as high quality evidence,
whereas those from studies with other designs (observational
studies) start as low quality evidence. According to a set of prede-
fined criteria, evidence quality could be increased or decreased. In
order to assess the best available evidence, we used the results of
the confounder-adjusted analyses to determine GRADE evidence
quality.74242.8. Statistical analysis
RRs and corresponding 95%CIs (Confidence interval) were calcu-
lated or extracted directly from the publications. Hazard ratios and
risk ratios were considered interchangeable in the analyses. Odds
ratio(OR) were converted into risk ratio by the formula risk
ratio = OR/[(1  P0) + (P0 * OR)], in which P0 was the event inci-
dence in the control group [14].
Where data frommore than one study for a given outcomewere
available, we performed a meta-analysis. Heterogeneity between
trials was identified by the v2 test. For each outcome measure of
interest, random effects meta-analysis was conducted to pool RRs
for the dichotomous composite outcome (all-cause mortality, car-
diovascular events, incident pneumonia) in order to determine the
effect of PV (yes/no) or PV combined with IV (yes/no) if hetero-
geneity (I2 > 50%). Fixed-effect model was used when heterogene-
ity was acceptable (I2  50%). Descriptive analysis was performed
in cases of unacceptable heterogeneity. Publication bias was
assessed by using funnel plots. Calculations were done by STATA
15 (StataCorp, College Station, TX, USA).3. Results
3.1. Selection of studies
Initially we identified a total of 7,869 records in electronic data-
bases and no additional studies from the reference list. We finally
included six studies after applying the inclusion and exclusion cri-
teria. The reasons for excluding studies are reported in Fig. 1.
3.2. Study characteristics
Six studies were included, with five retrospective cohort studies
[15–19] and one quasi-RCT [20] enrolling 394,299 patients in total.
Two studies were conducted in the US [15,16], while other studies
were in China [17], Czech Republic [18], Japan [19] and Belgium
[20], respectively (Table 1). Most included participants were above
60 years old. The duration of dialysis was more than 90 days and
the proportion of males ranged from 52.5 to 67.8% [15,16,19,20].
Four studies enrolled HD patients only [15,17,18,20] while one
study also enrolled 7.3% PD patients [16] and one study had no
description of dialysis modality [19]. Regarding pneumococcal vac-
cine types, three studies compared PPV23 with no vaccination [17–
19], one study compared PPV23 with PCV13 [20], and the other
two did not report what types of PV had been used [15,16]. Two
studies investigated the combined effect of PV and IV [15,16].
As for reported outcomes, eleven different clinical outcomes
were reported (Supplementary Table 1. All-cause mortality [15–
17,19,20], cardiovascular disease [15,17,19], pneumonia outcomes
[15,17,19,20] and antibody response [18,20] were addressed by at
least two studies, whereas only one study reported infectious
death [15], other-cause death [15], all-cause hospitalization [15],
bacteremia/septicemia hospitalization [15], respiratory infection
hospitalization [15], cerebrovascular events [17], and adverse
effects [20]).
3.3. Risk of bias assessment
Risks of bias assessment of included studies were shown in
Table 1 and Supplementary Table 2. The quality of the included
observational studies was moderate to high according to the NOS
criteria (three studies with high quality [15,16,19] and three stud-
ies with moderate quality [17,18,20]). The common issues identi-
fied included lack of representativeness of the exposed cohort
[17–20], no description on variables considered in analysis
Records idenfied through English database: 
Pubmed: 1975; Cochrane: 449; Embase: 4768.
Records idenfied through Chinese database:
CNKI: 224; Wang fang: 227; CMB: 226. 
Total: n = 7869. 
Addional records idenfied 
through other sources  
(n = 0)
Records aer duplicates removed (n = 6502) 
Records excluded (n = 6231)  
- Not about pneumococcal vaccine (n=4447) 
- Not about CKD (n=1601) 
- Review or meta-analysis of other vaccine 
or other disease (n=183) 
Records aer 
tle-abstract assessed  
(n = 271) 
Records excluded (n =259) 
-Case report (n=8) 
-Not about effecveness or safety, like 
vaccinaon coverage (n=74) 
- Guideline or review (n=87) 
- Focus on risk people but no final data 
about CKD (n=27) 
- Before vs aer vaccinaon (n=17) 
- Nephroc syndrome vs healthy control 
(n=18) 
- CKD vs healthy control (n=3)  
- Dialysis vs healthy control (n=3) 
- Renal transplantaon vs healthy control 
(n=5) 
- Dialysis vs CRF (n=2) 
- Dialysis vs renal transplantaon (n=4)   
- Comparisons among >2 groups of 
paents (n=11) 
Studies included in for 
further assessment  
(n =12) 
Studies included in final synthesis  
(n =6 ) 
Records excluded (n = 6)  
- Not dialysis paents (n=4) 
- Data in the same study (n=1) 
- Protocol (n=1) 
Fig. 1. Flow chart for the systematic literature search and study selection related to pneumococcal vaccine effectiveness outcomes in dialysis patients.
Y. Mo, J. Zeng, C. Xiao et al. Vaccine 38 (2020) 7422–7432[17,18,20] and short duration of follow-up [15,18]. For Vandecas-
teele’s study, the RCT part was moderate risk with unclear alloca-
tion concealment, blinding of participants and personnel and
blinding of outcome assessment; and the observational study part
was moderate risk because of no description of ascertainment of
exposure and no description on variables considered in analysis
[20].
3.4. All-cause mortality
Compared with controls, PV was associated with lower all-
cause mortality in dialysis patients with low heterogeneity from
four studies (pooled RR:0.73, 95% CI: 0.67–0.79, I2 = 31.1%,
P = 0.225, GRADE low certainty) [15–17,19] (Fig. 2, Supplementary
Fig. 1 and Supplementary Table 3).7425Compared with control dialysis patients, those who received
either PV only or received both PV and IV were associated with a
lower mortality. The pooled RRs of death from two studies
[15,16] were 0.76 (95%CI: 0.73–0.79, I2 = 0, P = 0.78), 0.86 (95%
CI: 0.78–0.94, I2 = 0, P = 0.34), and 0.71 (95%CI: 0.67–0.75,
I2 = 63.3%, P = 0.09) in those receiving IV only, PV only and both
vaccines, respectively (Fig. 2 and Supplementary Fig. 1).
3.5. Cardiovascular events
Compared with non-pneumococcal vaccination, PV was associ-
ated with lower odds of cardiovascular events (pooled RR:0.80, 95%
CI: 0.69–0.93, I2 = 47.2, P = 0.42, GRADE low quality) [15,17,19] in
dialysis patients (Fig. 3, Supplementary Fig. 2 and Supplementary
Table 3).
Table 1
Characteristics of included studies on effectiveness and safety of pneumococcal vaccination in dialysis patients.
Author, year [Ref] Country Study
design
















































































































































Hsieh, 2016 [17] Taiwan,
China







P-: n = 377.
(100%)










Trmal, 2005 [18] Czech cohort Not reported NR NR Not reported P+/I+:35;
P-/I+:19.
(100%)
12 months PPV23 Antibody
response
/ / Moderate
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Abbreviations: HD: hemodialysis; HCPCS: Current Procedural Terminology/Health Care Common Procedure Coding System; ESKD: end stage kidney disease; PPV: polysaccharide pneumococcal vaccine; PCV: pneumococcal
conjugate vaccine; CMS: Centers for Medicare & Medicaid Services; ELISA: Enzyme-linked Immunosorbent Assay; OPA: Opsonophagocytic Assay; NR: not reported; P+: receive pneumococcal vaccination with/without influenza
vaccination; P: not receive pneumococcal vaccination with/without influenza vaccination; P-/I: receive neither vaccination; P+/I: only receive pneumococcal vaccination but no influenza vaccination; P/I+: only receive
influenza vaccination but no pneumococcal vaccination; P+/I+: receive both vaccinations.
a Total study population: 394,299 (P+: 279,986; P: 114,313).
b Group 1: PPV-23-naive patients receiving PPV23; Group 2: PPV-23-naive patients receiving PCV13; Group 3: Patients who pre-vaccinated with PPV-23 > 4 years receiving PCV13; Group 4: Patients who pre-vaccinated with













Fig. 2. Forest plots depicting the association between pneumococcal vaccine used alone or combined with influenza vaccine and all-cause mortality in dialysis patents (fixed-
effect model).
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There was no difference between pneumococcal vaccinated
patients vs non-vaccinated patients with respect to incident pneu-
monia (RR < 1, P > 0.05) [17], pneumonia hospitalization (pooled
RR:1.32, 95%CI: 0.73–2.00, I2 = 43.3%, P = 0.184, GRADE low cer-
tainty) [15,19] or pneumonia death(RR:1, 95%CI: 0.32–3.10) [19]
(Fig. 4, Supplementary Fig. 3 and Supplementary Table 3).
3.7. Antibody response
Two studies reported antibody response [18,20]. The geometric
mean concentrations of antibodies to PV increased 4.8 times after
vaccination for dialysis patients but decreased to 1/3 one year later
[18]. In those pneumococcal vaccination naive dialysis patients
randomized to receive PCV13 or PPV23, ELISA antibody titers were
significantly higher among PCV13 than PPV23 recipients for six
serotypes (1.85-2.34 fold) after 28 days, and remained significantly
higher for one serotype (1.57-fold) after 365 days [20]. Following
PCV-13 vaccination, increases in ELISA antibody titers were signif-
icantly higher among PPV-23-naive versus PPV-23-pre-vaccinated
patients for 12 serotypes after 28 days (1.68–7.74-fold) and
remained significantly higher in ten serotypes (1.44–3.29-fold)
after 365 days [20]. Immune response to PCV-13 was weaker in
PPV-23-pre-vaccinated compared with vaccine-naive patients.74283.8. Safety
One study reported adverse effects of PV, including pain, fati-
gue, muscle aches, headache, itching and decreased mobility [20].
Local adverse effects, especially pain and decreased mobility,
occurred in up to one-fifth of the patients, mainly during the first
3 days after vaccination. Local adverse effects, especially pain,
tended to be more common in the PCV-13 groups than in the
PPV-23 group.
3.9. Publication bias
Formal testing for publication bias was not performed because
of the small number of identified studies.
4. Discussion
Our results indicated that PV was associated with reduced risks
of all-cause mortality and cardiovascular events but made little dif-
ference to pneumonia with low certainty evidence. A lower risk of
all-cause mortality was observed in those receiving PV combined
with IV. For PV recipients, geometric mean concentrations of anti-
bodies increased 4.8 times thereafter but decreased to 1/3 a year
later. Compared with those vaccinated with PPV-23, those receiv-
ing PCV-13 had higher ELISA antibody titers of some serotypes
Fig. 3. Forest plots depicting the association between pneumococcal vaccine and cardiovascular disease in dialysis patents (fixed-effect model).
Fig. 4. Forest plots depicting the association between pneumococcal vaccine and pneumonia in dialysis patents (fixed-effect model).
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Y. Mo, J. Zeng, C. Xiao et al. Vaccine 38 (2020) 7422–7432after 28 and 365 days. No serious adverse effect of PV was
reported.
Our analysis demonstrated that use of PV was associated with
lower risks of all-cause mortality and cardiovascular events. First,
previous studies have reported a higher risk of acute cardiac events
following pneumonia in both the general and dialysis population
[21,22]. PV may reduce the incidence of cardiovascular events by
minimizing the severity of the pneumonia and its associated
systematic inflammation [23,24]. Second, Reyes et al have found
S. pneumoniae invaded the myocardium and induced cardiac
injury with necroptosis and apoptosis in a non-human primate
model. PV may prevent S. pneumoniae invading cardiac tissue
[25]. Furthermore, vaccination with S. pneumoniae appears to
induce the production of antibodies that cross-react with oxidized
low density lipoprotein, a component of atherosclerotic plaques,
resulting in reduced cardiovascular events [26]. Similar mecha-
nisms have been identified with IV [27,28] and this may explain
the observed reduced mortality in dialysis patients receiving a
combination of IV and PV compared with either agent alone. How-
ever, our data did not support that this is the mechanism as there
was no association with pneumonia-related outcomes. It may be
instead that those patients who agreed to vaccination are more
health literate and have associated better cardiovascular and all-
cause mortality outcomes (healthy vaccinee bias). It is also possible
that patients receiving a combination of IV and PV were more
likely to be cared for by healthcare professionals who adhered to
other best practice guideline recommendations (e.g. phosphate,
anemia and blood pressure) that are associated with reduced mor-
tality and cardiovascular disease in dialysis patients. Therefore,
further RCTs are needed to evaluate its efficacy in this population
objectively.
Our result of pneumonia outcomes that PV made no difference
with respect to incident pneumonia was consistent with the find-
ing in the elderly or patients with chronic diseases [29,30]. PV may
not be effective in reducing the incident pneumonia in dialysis
patients, but may reduce the mortality by minimizing the severity
of the infection, similar to that in HIV patients and older adults
[23,24]. In addition, PV can only induce certain serotype conver-
sion and exert a protective effect [30,31]. The lack of serotype cov-
erage from PV in specific area may also contribute to the null
effects of PV. For example, a Japanese study showed that the sero-
types addressed by PPV-23 (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A,
12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23) only accounted for less
than 51% of all pneumococcal pneumonia serotypes in adults [32].
Patients infected with serotype 6A pneumococcal pneumonia,
which was not covered by PPV23, had a 25% higher risk of death
than patients infected with other serotypes [32]. The included
studies in our analysis only focused on all-cause pneumonia, but
not certain serotypes of pneumococcal pneumonia. Another possi-
ble reason for why we did not observe lower pneumonia incidence
and morbidity in vaccinated patients could be the effect of indica-
tion bias (i.e. patients with underlying comorbidities may have
been more likely to have been vaccinated than healthier study par-
ticipants). This could have biased the study findings in favour of
the null hypothesis. Therefore, well-designed studies are needed
to confirm the effectiveness of PV against serotype-specific pneu-
monia in dialysis patients.
Regarding type of PV, our systematic review showed PCV-13
seems to be more immunogenic than PPV-23 among vaccine-
naive hemodialysis patients, which is similar to what has been pre-
viously demonstrated in immunocompetent adults [33]. As we
know, PPV induces immunoreaction without the involvement of
T cells, so PPV cannot sustain long-term immunity and cannot be
enhanced through additional vaccination [34]. PCV elicits a T-cell
dependent response resulting in memory B-cell formation and
higher avidity of antibody production [35]. Therefore, it is possible7430that PCV may lead to a more durable antibody response compared
to PPV. Secondly, immune response to PCV-13 is weaker in PPV23-
pre-vaccinated compared with vaccine-naive patients. It has been
reported that the responses to PCV-13 after PPV-23 vaccination
were significantly lower than those initializing PCV-13 vaccination,
which suggested that PPV-23 might diminish the response of sub-
sequent PCV-13 vaccination [36]. Giving a PCV prior to a PPV has
the potential to enhance the immune response to the PPV by stim-
ulating memory B cells and priming the immune system, such that
a vaccination combination of PCV-13 first and PPV-23 second is
recommended for immunocompromised patients [37,38].
As for the timing of revaccination, our results showed the titers
of antibody related to vaccination decreased quickly over time in
dialysis patients, similar to previous studies [8,9]. The current
guideline recommends revaccination in five years after first pneu-
mococcal vaccination [6,37]. However, there are insufficient data
to show whether this five-year interval is too long for dialysis
patients and the levels of antibody required for protection have
not been clearly delineated. Therefore, whether we should shorten
the time for revaccination by monitoring titers of antibody has yet
to be confirmed and needs further studies.
As for safety, similar to the findings of previous meta-analyses
[33,39], we found that PV has a high safety profile, with local reac-
tions at the injection site, and rare systemic side effects, such as fever.
4.1. Policy implication
PV was cost-effective among adults aged 50–64 years with CKD
even when assuming the lowest vaccine efficacy [40]. However, PV
coverage is low in many countries [41–43]. The results of our cur-
rent study might raise awareness about the importance of pneu-
mococcal vaccinations. Given its benefit of lower mortality and
mild side effects, PV combined with IV seems to be beneficial for
dialysis patients. Though PV is recommended to dialysis patients
in global and national guidelines [6,7,37], the evidence to date is
only low certainty according to the GRADE criteria. For policy mak-
ers, considering the indication bias and healthy vaccine bias of the
observational studies, well-designed and adequately powered ran-
domized control trials are needed to reduce uncertainty about its
efficacy on risk of pneumonia and the time for revaccination in this
population.
4.2. Strengths and limitation
Our study has several strengths. Our systematic review focused
on PV in dialysis patients, a neglected population in previous sys-
tematic reviews. We performed comprehensive searches using
not only English databases such as PubMed and Embase, but also
Chinese databases to capture as many relevant studies as possible.
Moreover, we performed an outcome-specific quality assessment
of individual studies and considered the certainty of the body of
evidence for each outcome by using GRADE. We have also covered
a wide range of clinically important questions about vaccinations
in dialysis patients, including effectiveness, the benefit if combined
with influenza vaccination, which types (PPV or PCV) to use and
the possible timing of revaccination.
We also acknowledged the following limitations should be con-
sidered when interpreting our findings: First, most included stud-
ies were retrospective cohort studies. Our data cannot prove
causality and the possibility of residual or unmeasured confound-
ing cannot be eliminated. We were unable to further investigate
the effect of indication bias and healthy vaccinee bias, which might
underestimate or overestimate the effectiveness of pneumococcal
vaccine [44,45]. Second, we used the most adjusted RR as the esti-
mator in our meta-analysis, which may have resulted in outcome
reporting bias despite representing the most conservative risk esti-
Y. Mo, J. Zeng, C. Xiao et al. Vaccine 38 (2020) 7422–7432mation. Third, we found overall moderate to high heterogeneity in
some estimates. Heterogeneity may be attributed in part to differ-
ent patient characteristics, follow-up periods, study quality and
sample size and intervention type. However, we were unable to
perform all these subgroup analyses owing to the limited data
available and lack of access to the original, individual patient data.
Fourth, patients included were from developed countries or
regions. It should be cautious for the interpretation of our data in
less-developed countries. Finally, although we have tried to sum-
marize all of the available evidence, it should be noted that the
number of included studies limited our ability to perform further
meta-analysis. The interpretation of the results should take into
consideration the fact that the results for all-cause mortality were
largely driven by two studies [15,16], the results for cardiovascular
disease and pneumonia hospitalization were restricted to one large
study [15], the results for pneumonia incidence [17] and death [19]
were limited to only one observational study each, safety was
addressed by only one study [20], and antibody response was
addressed by two studies [18,20]. Meanwhile the study sample
was too small to formally test for publication bias, this form of bias
cannot be ruled out.
5. Conclusion
The use of pneumococcal vaccine, especially combined with
influenza vaccine, is associated with lower risks of all-cause mor-
tality. High quality randomized controlled trials are needed to pro-
vide high certainty evidence regarding the effectiveness and safety
of pneumococcal vaccines used alone or in combination with influ-
enza vaccination in dialysis patients.
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